Publicaciones en colaboración con investigadores/as de Hospital Universitario Pío del Río Hortega (20)

2024

  1. COVID-19-associated pulmonary aspergillosis (CAPA) in hematological patients: Could antifungal prophylaxis be necessary? A nationwide study

    Journal of Infection and Public Health, Vol. 17, Núm. 6, pp. 939-946

2020

  1. Use of eltrombopag for patients 65 years old or older with immune thrombocytopenia

    European Journal of Haematology, Vol. 104, Núm. 3, pp. 259-270

2018

  1. Polymorphisms in receptors involved in opsonic and nonopsonic phagocytosis, and correlation with risk of infection in oncohematology patients

    Infection and Immunity, Vol. 86, Núm. 12

2017

  1. Efficacy and safety of eltrombopag in persistent and newly diagnosed ITP in clinical practice

    International Journal of Hematology, Vol. 106, Núm. 4, pp. 508-516

2016

  1. Eltrombopag safety and efficacy for primary chronic immune thrombocytopenia in clinical practice

    European Journal of Haematology, Vol. 97, Núm. 3, pp. 297-302

2015

  1. Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia

    American Journal of Hematology, Vol. 90, Núm. 3, pp. E40-E43

2010

  1. Long FLT3 internal tandem duplications and reduced PML-RARα expression at diagnosis characterize a high-risk subgroup of acute promyelocytic leukemia patients

    Haematologica, Vol. 95, Núm. 5, pp. 745-751

2009

  1. Efficacy and safety of Liposomal cytarabine in lymphoma Patients with central nervous system involvement from lymphoma

    Cancer, Vol. 115, Núm. 9, pp. 1892-1898

  2. Hematologic and cytogenetic response to lenalidomide in de novo acute myeloid leukemia with chromosome 5q deletion

    Leukemia Research

  3. High FOXO3a expression is associated with a poorer prognosis in AML with normal cytogenetics

    Leukemia Research, Vol. 33, Núm. 12, pp. 1706-1709

  4. Influence of MBL-2 mutations in the infection risk of patients with follicular lymphoma treated with rituximab, fludarabine, and cyclophosphamide

    Leukemia and Lymphoma, Vol. 50, Núm. 8, pp. 1283-1289

  5. Molecular stratification model for prognosis in cytogenetically normal acute myeloid leukemia

    Blood, Vol. 114, Núm. 1, pp. 148-152

2008

  1. The relevance of preferentially expressed antigen of melanoma (PRAME) as a marker of disease activity and prognosis in acute promyelocytic leukemia

    Haematologica, Vol. 93, Núm. 12, pp. 1797-1805

2006

  1. Diagnosis of a primary testicular lymphoma by echography and magnetic resonance imaging

    Clinical and Translational Oncology, Vol. 8, Núm. 6, pp. 456-458

  2. Oral anticoagulant treatment: Risk factors involved in 500 intracranial hemorrhages

    Journal of Thrombosis and Thrombolysis, Vol. 22, Núm. 2, pp. 113-120

2004

  1. Experimental and clinical regenerative capability of human bone marrow cells after myocardial infarction

    Circulation Research, Vol. 95, Núm. 7, pp. 742-748

  2. Intracoronary stem cell transplantation in acute myocardial infarction

    Revista Espanola de Cardiologia, Vol. 57, Núm. 3, pp. 201-208

2003

  1. A randomized study of intermediate as compared with high doses of interferon-alpha for chronic myeloid leukemia: No differences in cytogenetic responses

    Annals of Hematology, Vol. 82, Núm. 12, pp. 750-758

  2. Emphysematous gastritis and severe aplastic anemia

    Hematology Journal, Vol. 4, Núm. 1, pp. 82-84

  3. Marrow versus peripheral blood for geno-identical allogeneic stem cell transplantation in acute myelocytic leukemia: Influence of dose and stem cell source shows better outcome with rich marrow

    Blood, Vol. 102, Núm. 8, pp. 3043-3051